Search Results - "THADDEUS BECK, J"

Everolimus-based combination therapies for HR+, HER2− metastatic breast cancer by O'Shaughnessy, Joyce, Thaddeus Beck, J., Royce, Melanie

“…•Everolimus plus exemestane is an established treatment for NSAI-resistant MBC.•New everolimus-based combinations under investigation will expand treatment…”
Get full text

Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer by Slamon, Dennis J, Neven, Patrick, Chia, Stephen, Fasching, Peter A, De Laurentiis, Michelino, Im, Seock-Ah, Petrakova, Katarina, Bianchi, Giulia V, Esteva, Francisco J, Martín, Miguel, Nusch, Arnd, Sonke, Gabe S, De la Cruz-Merino, Luis, Beck, J. Thaddeus, Pivot, Xavier, Sondhi, Manu, Wang, Yingbo, Chakravartty, Arunava, Rodriguez-Lorenc, Karen, Taran, Tetiana, Jerusalem, Guy

“…An earlier report documented significant improvement in progression-free survival among patients with metastatic breast cancer treated with fulvestrant and a…”
Get full text

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer by Baselga, José, Campone, Mario, Piccart, Martine, Burris, Howard A, Rugo, Hope S, Sahmoud, Tarek, Noguchi, Shinzaburo, Gnant, Michael, Pritchard, Kathleen I, Lebrun, Fabienne, Beck, J. Thaddeus, Ito, Yoshinori, Yardley, Denise, Deleu, Ines, Perez, Alejandra, Bachelot, Thomas, Vittori, Luc, Xu, Zhiying, Mukhopadhyay, Pabak, Lebwohl, David, Hortobagyi, Gabriel N

“…Resistance to hormone therapy through activation of cellular pathways involving mTOR can develop in postmenopausal hormone-receptor–positive breast cancer…”
Get full text

Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3 by Slamon, Dennis J, Neven, Patrick, Chia, Stephen, Fasching, Peter A, De Laurentiis, Michelino, Im, Seock-Ah, Petrakova, Katarina, Bianchi, Giulia Val, Esteva, Francisco J, Martín, Miguel, Nusch, Arnd, Sonke, Gabe S, De la Cruz-Merino, Luis, Beck, J Thaddeus, Pivot, Xavier, Vidam, Gena, Wang, Yingbo, Rodriguez Lorenc, Karen, Miller, Michelle, Taran, Tetiana, Jerusalem, Guy

“…Purpose This phase III study evaluated ribociclib plus fulvestrant in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative…”
Get full text

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years by Goss, Paul E, Ingle, James N, Pritchard, Kathleen I, Robert, Nicholas J, Muss, Hyman, Gralow, Julie, Gelmon, Karen, Whelan, Tim, Strasser-Weippl, Kathrin, Rubin, Sheldon, Sturtz, Keren, Wolff, Antonio C, Winer, Eric, Hudis, Clifford, Stopeck, Alison, Beck, J. Thaddeus, Kaur, Judith S, Whelan, Kate, Tu, Dongsheng, Parulekar, Wendy R

“…An additional 5 years of adjuvant aromatase-inhibitor therapy in women with early hormone-receptor–positive breast cancer resulted in longer disease-free…”
Get full text

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study by Ascierto, Paolo A, MD, Schadendorf, Dirk, Prof, Berking, Carola, Prof, Agarwala, Sanjiv S, Prof, van Herpen, Carla ML, MD, Queirolo, Paola, MD, Blank, Christian U, MD, Hauschild, Axel, Prof, Beck, J Thaddeus, MD, St-Pierre, Annie, PhD, Niazi, Faiz, MPharm, Wandel, Simon, PhD, Peters, Malte, MD, Zubel, Angela, MD, Dummer, Reinhard, Prof

“…Summary Background Patients with melanoma harbouring Val600 BRAF mutations benefit from treatment with BRAF inhibitors. However, no targeted treatments exist…”
Get full text

Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial by Rugo, Hope S, Dr Prof, Seneviratne, Lasika, MD, Beck, J Thaddeus, MD, Glaspy, John A, Prof, Peguero, Julio A, MD, Pluard, Timothy J, MD, Dhillon, Navneet, MD, Hwang, Leon Christopher, MD, Nangia, Chaitali, MD, Mayer, Ingrid A, MD, Meiller, Timothy F, Prof, Chambers, Mark S, Prof, Sweetman, Robert W, MD, Sabo, J Randy, MPH, Litton, Jennifer K, MD

“…Summary Background Stomatitis is a class effect associated with the inhibition of mTOR and is associated with everolimus therapy for breast cancer. Topical…”
Get full text

A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer by Kuemmel, Sherko, Campone, Mario, Loirat, Delphine, Lopez, Rafael Lopez, Beck, J Thaddeus, De Laurentiis, Michelino, Im, Seock-Ah, Kim, Sung-Bae, Kwong, Ava, Steger, Guenther G, Adelantado, Esther Zamora, Duhoux, Francois P, Greil, Richard, Kuter, Irene, Lu, Yen-Shen, Tibau, Ariadna, Özgüroğlu, Mustafa, Scholz, Christian W, Singer, Christian F, Vega, Estela, Wimberger, Pauline, Zamagni, Claudio, Couillebault, Xuan-Mai, Fan, Liqiong, Guerreiro, Nelson, Mataraza, Jennifer, Sand-Dejmek, Janna, Chan, Arlene

“…This phase II study determined the efficacy of lacnotuzumab added to gemcitabine plus carboplatin (gem-carbo) in patients with advanced triple-negative breast…”
Get full text

Final 5-Year Results of Z-FAST Trial: Adjuvant Zoledronic Acid Maintains Bone Mass in Postmenopausal Breast Cancer Patients Receiving Letrozole by BRUFSKY, Adam M, GRAYDON HARKER, W, ERICSON, Solveig G, PEREZ, Edith A, THADDEUS BECK, J, BOSSERMAN, Linda, VOGEL, Charles, SEIDLER, Christopher, LIXIAN JIN, WARSI, Ghulam, ARGONZA-AVILES, Eliza, HOHNEKER, John

“…Postmenopausal breast cancer (BC) patients receiving adjuvant aromatase inhibitor therapy are at risk of progressive bone loss and fractures. Zoledronic acid…”
Get full text

PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer by Zinner, Ralph G, Obasaju, Coleman K, Spigel, David R, Weaver, Robert W, Beck, J Thaddeus, Waterhouse, David M, Modiano, Manuel R, Hrinczenko, Borys, Nikolinakos, Petros G, Liu, Jingyi, Koustenis, Andrew G, Winfree, Katherine B, Melemed, Symantha A, Guba, Susan C, Ortuzar, Waldo I, Desaiah, Durisala, Treat, Joseph A, Govindan, Ramaswamy, Ross, Helen J

“…PRONOUNCE compared the efficacy and safety of pemetrexed+carboplatin followed by pemetrexed (Pem+Cb) with paclitaxel+carboplatin+bevacizumab followed by…”
Get more information

Zoledronic Acid Inhibits Adjuvant Letrozole–Induced Bone Loss in Postmenopausal Women With Early Breast Cancer by BRUFSKY, Adam, HARKER, W. Graydon, BECK, J. Thaddeus, CARROLL, Robert, TAN-CHIU, Elizabeth, SEIDLER, Christopher, HOHNEKER, John, LACERNA, Leo, PETRONE, Stephanie, PEREZ, Edith A

“…Treatment with aromatase inhibitors decreases bone mineral density (BMD) and may increase the risk of fractures in postmenopausal women with early-stage breast…”
Get full text

Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study by Fasching, Peter A., Beck, J. Thaddeus, Chan, Arlene, De Laurentiis, Michele, Esteva, Francisco J., Jerusalem, Guy, Neven, Patrick, Pivot, Xavier, Bianchi, Giulia V., Martin, Miguel, Chandiwana, David, Lanoue, Brad, Ridolfi, Antonia, Wang, Yingbo, Rodriguez Lorenc, Karen, Nusch, Arnd

“…In the MONALEESA-3 Phase III trial of patients with hormone receptor–positive human epidermal growth factor receptor–negative advanced breast cancer,…”
Get full text

The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma by Voss, Martin H, Bhatt, Rupal S, Plimack, Elizabeth R, Rini, Brian I, Alter, Robert S, Beck, J Thaddeus, Wilson, Dawn, Zhang, Xiaosha, Mutyaba, Musa, Glasser, Chad, Attie, Kenneth M, Sherman, Matthew L, Pandya, Shuchi S, Atkins, Michael B

“…Activin receptor-like kinase 1 (ALK1) is a novel target in angiogenesis. Concurrent targeting of ALK1 and VEGF signaling results in augmented inhibition of…”
Get full text

Artificial Intelligence Tool for Optimizing Eligibility Screening for Clinical Trials in a Large Community Cancer Center by Beck, J Thaddeus, Rammage, Melissa, Jackson, Gretchen P, Preininger, Anita M, Dankwa-Mullan, Irene, Roebuck, M Christopher, Torres, Adam, Holtzen, Helen, Coverdill, Sadie E, Williamson, M Paul, Chau, Quincy, Rhee, Kyu, Vinegra, Michael

“…Less than 5% of patients with cancer enroll in clinical trials, and 1 in 5 trials are stopped for poor accrual. We evaluated an automated clinical trial…”
Get more information

Sorafenib or Placebo with Either Gemcitabine or Capecitabine in Patients with HER-2―Negative Advanced Breast Cancer That Progressed during or after Bevacizumab by SCHWARTZBERG, Lee S, TAUER, Kurt W, BELL-MCGUINN, Katherine, KIRSHNER, Jeffrey J, EISENBERG, Peter, EMANUELSON, Richard, KEATON, Mark, LEVINE, Ellis, MEDGYESY, Diana C, QAMAR, Rubina, STARR, Alexander, SUNHEE KWON RO, HERMANN, Robert C, LOKKER, Nathalie A, HUDIS, Clifford A, MAKARI-JUDSON, Grace, ISAACS, Claudine, THADDEUS BECK, J, KAKLAMANI, Virginia, STEPANSKI, Edward J, RUGO, Hope S, WEI WANG

“…We assessed adding the multikinase inhibitor sorafenib to gemcitabine or capecitabine in patients with advanced breast cancer whose disease progressed…”
Get full text

Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study by Tolaney, Sara M, Beeram, Muralidhar, Beck, J Thaddeus, Conlin, Alison, Dees, E Claire, Puhalla, Shannon L, Rexer, Brent N, Burris, Howard A, Jhaveri, Komal, Helsten, Teresa, Becerra, Carlos, Kalinsky, Kevin, Moore, Kathleen N, Manuel, Allison M, Lithio, Andrew, Price, Gregory L, Chapman, Sonya C, Litchfield, Lacey M, Goetz, Matthew P

“…Cyclin-dependent kinases (CDK) 4 and 6 regulate G1 to S cell cycle progression and are often altered in cancers. Abemaciclib is a selective inhibitor of CDK4…”
Get full text

Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS - or BRAF -mutated melanoma by van Herpen, Carla M L, Agarwala, Sanjiv S, Hauschild, Axel, Berking, Carola, Beck, J Thaddeus, Schadendorf, Dirk, Jansen, Rob, Queirolo, Paola, Ascierto, Paolo A, Blank, Christian U, Heinrich, Michael C, Pal, Rupam R, Derti, Adnan, Antona, Victor, Nauwelaerts, Heidi, Zubel, Angela, Dummer, Reinhard

“…and are the most frequently mutated mitogen-activated protein kinase (MAPK) genes in melanoma. Binimetinib is a highly selective MAPK kinase (MEK) 1/2…”
Get full text

Phase 1B/2 study of the HSP90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab-based regimen by Kong, Anthony, Rea, Daniel, Ahmed, Samreen, Beck, J Thaddeus, López López, Rafael, Biganzoli, Laura, Armstrong, Anne C, Aglietta, Massimo, Alba, Emilio, Campone, Mario, Hsu Schmitz, Shu-Fang, Lefebvre, Caroline, Akimov, Mikhail, Lee, Soo-Chin

“…This open-label, multicenter, phase 1B/2 trial assessed AUY922 plus trastuzumab in patients with locally advanced or metastatic HER2-positive breast cancer…”
Get full text

Abemaciclib in Combination With Pembrolizumab for Stage IV KRAS-Mutant or Squamous NSCLC: A Phase 1b Study by Pujol, Jean-Louis, Vansteenkiste, Johan, Paz-Ares Rodríguez, Luis, Gregorc, Vanesa, Mazieres, Julien, Awad, Mark, Jänne, Pasi A., Chisamore, Michael, Hossain, Anwar M., Chen, Yanyun, Beck, J. Thaddeus

“…Abemaciclib is an oral, selective small-molecule CDK 4 and 6 inhibitor. In preclinical models, abemaciclib synergized with programmed cell death protein-1…”
Get full text

676 Pepinemab, a semaphorin 4D inhibitor, in combination with pembrolizumab induced formation of organized lymphoid aggregates in phase 1b/2 study for first-line treatment of R/M HNSCC (KEYNOTE-B84) by Fisher, Terrence, Evans, Elizabeth, Mallow, Crystal, Foster, Amber, Leonard, John, Chaney, Marya, Mekhail, Tarek, Seetharamu, Nagashree, Steuer, Conor, Saba, Nabil F, Adkins, Douglas, Thaddeus Beck, J, Algazi, Alain, Burtness, Barbara, Baumgart, Megan, Hager, Steven, Chay, Christopher, Spira, Alexander, Zauderer, Maurice

“…BackgroundImmunosuppressive myeloid cells in the tumor microenvironment (TME) limit the efficacy of immune checkpoint inhibitors (ICIs) in head and neck…”
Get full text